[go: up one dir, main page]

WO2022189010A1 - Méthodes et compositions pour le traitement et la prévention d'infections des voies urinaires - Google Patents

Méthodes et compositions pour le traitement et la prévention d'infections des voies urinaires Download PDF

Info

Publication number
WO2022189010A1
WO2022189010A1 PCT/EP2021/071313 EP2021071313W WO2022189010A1 WO 2022189010 A1 WO2022189010 A1 WO 2022189010A1 EP 2021071313 W EP2021071313 W EP 2021071313W WO 2022189010 A1 WO2022189010 A1 WO 2022189010A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
cranberry
component
urinary tract
animal
Prior art date
Application number
PCT/EP2021/071313
Other languages
English (en)
Inventor
Douglas Andrew Klaiber
Emilie Annie Claudie Fromentin
Elias Duban ATALA RIFFO
Cristina Maria RANZINI
Manon LECOMTE
Original Assignee
Givaudan Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Givaudan Sa filed Critical Givaudan Sa
Publication of WO2022189010A1 publication Critical patent/WO2022189010A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Urinary tract infections are among the most common infectious diseases, and account for considerable healthcare outlays for society. Microorganisms can reach the urinary tract by a hematogenous or a lymphatic route, but most clinical and experimental evidence shows that ascension of the urethra by microorganisms constitutes the most common route leading to urinary tract infection, in particular by enteric organisms (Escherichia coli and other enterobacteria). Women are at greater risk of developing a UTI than are men.
  • LUTS lower urinary tract symptoms
  • BPH benign prostatic hyperplasia
  • LUTS can also arise from age-related bladder detrusor dysfunction and other sympathetic conditions.
  • LUTS are further classified as voiding or storage symptoms and defined by the international prostate symptoms score (IPSS), a validated tool, widely used among the medical and scientific community.
  • Voiding symptoms include urinary hesitancy, delay in initiating micturition, intermittency, involuntary interruption of voiding, weak urinary stream, straining to void, a sensation of incomplete emptying, terminal dribbling, and may be caused by prostate enlargement or tissue inflammation.
  • Storage symptoms can include urinary frequency, nocturia, urgency, incontinence and bladder pain or dysuria, and may be caused by bladder detrusor overactivity.
  • Overactive bladder is a condition more related with women where there is a frequent feeling of needing to urinate to a degree that it negatively affects a person's life.
  • the present invention relates to a composition (or composition of the disclosure) comprising a cranberry component and a saponin component, which is useful for the prevention or treatment of urinary tract infections, and in particular for the preventive treatment of urinary tract infections or treatment against the recurrence thereof.
  • the invention also relates to a process for preparing such composition, to food, nutraceutical or pharmaceutical compositions comprising said composition, and to use thereof in the treatment, alleviating or prevention of urinary tract infections, LUTS, OAB and other urinary tract complications and diseases.
  • the present disclosure is also based, in part, on the surprising discovery that lower urinary tract symptoms can be treated by administering a cranberry-based and saponin based composition.
  • the present disclosure is also based, in part, on the surprising discovery that lower urinary tract symptoms can be treated by administering a cranberry-based composition in combination with saponin based composition that modulates the microbiome.
  • the cranberry and the saponin components can help modulate the urinary and gut microbiome to prevent or help lower urinary tract symptoms or eradicate infections by promoting the restoration of a healthy flora.
  • composition comprising a cranberry component and a saponin component.
  • LUTS lower urinary tract symptoms
  • BPH benign prostatic hyperplasia
  • ED erectile dysfunction
  • OAB overactive bladder
  • bladder obstruction interstitial cystitis, underactive bladder, prostatitis, bladder inflammation, prostate inflammation, prostate fibrosis, pelvic pain, H.
  • pylori infection urolithiasis, hyperoxaluria and/or pelvic organ prolapse, and in particular for the preventive treatment of urinary tract infections, lower urinary tract symptoms (LUTS), the symptoms of benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, overactive bladder (OAB), bladder obstruction, interstitial cystitis, underactive bladder, prostatitis, bladder inflammation, prostate inflammation, prostate fibrosis, pelvic pain, H.
  • LUTS lower urinary tract symptoms
  • BPH benign prostatic hyperplasia
  • ED erectile dysfunction
  • OAB overactive bladder
  • bladder obstruction interstitial cystitis
  • underactive bladder prostatitis
  • bladder inflammation prostate inflammation
  • prostate fibrosis pelvic pain
  • a method for supporting genitourinary tract health in a human or animal in need thereof comprising administering to the human or animal an effective amount of a composition comprising a cranberry component and a saponin component.
  • the term “supporting genitourinary tract” refers to improving or preventing in a subject any problem related to the genitourinary tract such as urinary tract infection, lower urinary tract symptoms (LUTS), the symptoms of benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, overactive bladder (OAB), bladder obstruction, interstitial cystitis, underactive bladder, prostatitis, bladder inflammation, prostate inflammation, prostate fibrosis, pelvic pain, H. pylori infection, urolithiasis, hyperoxaluria and/or pelvic organ prolapse.
  • LUTS lower urinary tract symptoms
  • BPH benign prostatic hyperplasia
  • ED erectile dysfunction
  • OAB overactive bladder
  • bladder obstruction interstitial cystitis
  • underactive bladder prostatitis
  • bladder inflammation prostate inflammation
  • prostate fibrosis pelvic pain
  • H. pylori infection urolithiasis
  • a composition comprising a cranberry component and a saponin component in the manufacture of a medicament for use in method for preventing, treating or alleviating an urinary tract infection, lower urinary tract symptoms (LUTS), the symptoms of benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, overactive bladder (OAB), bladder obstruction, interstitial cystitis, underactive bladder, prostatitis, bladder inflammation, prostate inflammation, prostate fibrosis, pelvic pain, H. pylori infection, urolithiasis, hyperoxaluria and/or pelvic organ prolapse.
  • LUTS lower urinary tract symptoms
  • BPH benign prostatic hyperplasia
  • ED erectile dysfunction
  • OAB overactive bladder
  • bladder obstruction interstitial cystitis
  • underactive bladder prostatitis
  • bladder inflammation prostate inflammation
  • prostate fibrosis pelvic pain
  • H. pylori infection urolithiasis
  • a method for modulating or adjusting urinary and/or gut microbiota and/or reverting urinary tract and/or gut microbiome dysbiosis in a human or animal in need thereof comprising administering to the human or animal an effective amount of a composition (or composition of the disclosure) comprising a cranberry component and a saponin component.
  • composition comprising a cranberry component and a saponin component in the manufacture of a medicament for use in method for modulating or adjusting urinary tract and/or gut microbiota and/or reverting urinary tract and/or gut microbiome dysbiosis.
  • a method modulating or adjusting urinary tract and/or gut microbiota and/or reverting urinary tract and/or gut microbiome dysbiosis in a human or animal in need thereof, the method comprising administering to the human or animal an effective amount of a composition comprising a cranberry component and a saponin component and wherein.
  • the composition of the present disclosure can affect the human or animal genito -urinary microbiome or gut microbiome offering treatment lower urinary tract symptoms or for urinary tract infections.
  • composition of the present disclosure can affect the human or animal vaginal microbiome offering treatment for yeast infections, bacterial vaginosis and pelvic organ prolapse.
  • composition of the present disclosure can affect the human or animal urinary microbiome offering treatment for interstitial cystitis, prostatitis and pelvic organ prolapse.
  • composition of the present disclosure can affect the human or animal urinary and kidney microbiome offering treatment for urolithiasis and hyperoxaluria.
  • the animal is an alpaca, bison, cat, cow, chicken, dog, donkey, duck, fish, goat, horse, pheasant, pig, rabbit, sheep or turkey.
  • the cranberry component comprises cranberry powder or cranberry extract.
  • the composition further comprises a saponin component.
  • a saponin component included in the composition may comprise a quillaja saponin.
  • the infection is genitourinary infection.
  • the infection is caused by antimicrobial sensitive bacteria.
  • the infection is caused by antimicrobial resistant bacteria.
  • the method does not comprise administering an antimicrobial agent to the human or animal.
  • the method comprises combining the composition with an antimicrobial agent and administering to the human or animal.
  • the method comprises combining the composition with a probiotic and administering to the human or animal.
  • the infection is selected from H. pylori infection, cystic fibrosis, bacteremia, sepsis, yeast infections, bacterial vaginosis, and/or prostatitis (including bacterial prostatitis).
  • the composition further comprises a non-steroidal anti inflammatory agent.
  • the non-steroidal anti-inflammatory agent is ibuprofen.
  • the composition further comprises a probiotic agent.
  • the composition further comprises an antimicrobial agent.
  • the composition does not comprise an antimicrobial agent.
  • the composition further comprises an animal feed growth agent.
  • the antimicrobial agent is selected from the group consisting of b-lactam antimicrobial, carbapenems, penicillins, cephalosporins oxacephems, monobactums, penems, cycloserine, fosfomycin, glycopeptides, lipoglycopeptides, polymyxins, rifamycins, ansamycins, actinomycins, tiacumycins, quinolones, fluoroquinolones, aminocoumarins, lipamycins, sulfonamides, nitrofurantoin, nitrimidazole, aminoglycosides, tetracyclines, oxazolidinones, macrolides, thiopeptides, chloramphenicol, fusidic acid, clindamycin, lincosamides, glycylcyclines and beta-lactamase inhibitors.
  • the probiotic agent is selected from the group consisting of Bacillus coagulans, Akkermansia muciniphila, Lactobacillus gasseri, Bifidobacterium gifidum, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus GG, Lactobacillus plantarum 299V, Saccharomyces boulardi, Bifidobacterium infantis, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus reuteri, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus helveticus, Lactobacillus reuteri protectis , Lactobaccilus iners, Lactobaccilus amongsenii, Lactobacillus fermentum, Lactobacillus brevis, Lactobacillus casei, Lactobacillus vaginalis, Lac
  • the infection-causing bacterial strain is gram positive or gram negative.
  • the composition is a liquid, gel, tablet, a capsule, a sachet, a powder, a gum, an ointment, syrup, a suppository, a patch, a softgel, a tampon, a wound dressing, a wound rinse, a soap, or a lotion.
  • the invention provides a therapeutic composition formulated for use in the methods described herein.
  • the therapeutic composition is formulated for oral administration.
  • composition comprising a cranberry component and a saponin component
  • the cranberry component used in the present disclosure may be a cranberry juice, a cranberry puree, a cranberry powder, a cranberry extract or a combination thereof.
  • the cranberry powder is obtained from whole cranberry fruit.
  • the cranberry component may be in the form of a liquid or in the form of a powder.
  • the cranberry is Vaccinium macrocarpon. In some embodiments, the cranberry is Vaccinium microcarpon. In some embodiments, the cranberry is Vaccinium oxy coccus.
  • the cranberry component may be cranberry extract.
  • the extract obtained from the cranberries may be an aqueous extract, an alcohol extract (which includes hydro-alcoholic extracts) or an organic extract.
  • aqueous extract refers to the extract obtained from cranberry when the extraction from the plant has been performed using water as the only solvent.
  • alcohol extract refers to the extract obtained from cranberries when the extraction from the plant has been performed using an alcohol as the solvent.
  • the alcohol solvent may consist of only alcohol (e.g. 100% alcohol), for example 100% ethanol, or may be a mixture of an alcohol and water (i.e. a hydro -alcoholic solvent), for example, a mix of ethanol and water (hydro -ethano lie solvent), for example, from about 1% to about 99% alcohol (e.g.
  • the ratio of water to alcohol is from 10/90% v/v to 90/10% v/v or 30/70% v/v to 70/30% v/v, such as 50/50% v/v or 70/30 v/v.
  • organic extract refers to the extract obtained from cranberries when the extraction has been performed using an organic solvent that is not an alcohol.
  • the organic solvent may be selected from the group consisting of acetic acid, acetone, acetonitrile, benzene, 2-butanone, carbon tetrachloride, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethane, diethylene glycol, diethyl ether, diglyme (diethylene glycol, dimethyl ether), 1,2-dimethoxy- ethane (glyme, DME), dimethyl- formamide (DMF), dimethyl sulfoxide (DMSO), 1,4-dioxane, ethyl acetate, ethylene glycol, glycerin, heptane, hexamethylphosphoramide (HMPA), hexamethylphosphorous, triamide (HMPT), hexane,
  • HMPA hexamethylphosphoramide
  • the cranberry component may be an aqueous extract of cranberry. In another embodiment the cranberry component may be a purified cranberry extract. In one embodiment, the cranberry component has from about 1% to 30% proanthocyanidins, such as from about 3% to about 20%, or such as from about 3% to 15%, or 5% to 10% wt/wt. In one embodiment, the total phenolic of the cranberry component is from about 10% to about 60%, such as from about 20% to about 30% wt/wt.
  • the invention provides therapeutic composition comprising dried cranberry powder.
  • the cranberry component (such as a cranberry juice, a cranberry puree, a dried cranberry powder, whole cranberry powder or a cranberry extract) may be enriched with cranberry seeds or cranberry seed meal.
  • the seeds or seed meal concentration may be of 5%, 10%, 15%, 20%, 25%, 30% or 35% or more by weight of the total cranberry component.
  • the seeds or seed meal concentration may be from 5% to 35% by weight of cranberry component, such as from 10% to 25%, such as 20% of seeds or seed meal by weight of cranberry component.
  • the cranberry component may be a cranberry extract enriched in cranberry seeds or seed meal.
  • the seeds or seed meal concentration may be of 5%, 10%, 15%, 20%, 25, 30% or 35% or more by weight of cranberry component.
  • the seeds or seed meal concentration may be from 5% to 35% by weight of cranberry component, such as from 10% to 25%, such as 20% of seeds or seed meal by weight of cranberry component.
  • the cranberry component may be a cranberry extract enriched with about 20% cranberry seed or seed meal.
  • the cranberry component comprises dried cranberry powder (such as a dried cranberry powder from the whole cranberry fruit) and dried cranberry seeds or seeds meal.
  • the seeds or seed meal concentration may be of 5%, 10%, 15%, 20%, 25, 30% or 35% or more by weight of whole cranberry fruit powder.
  • the seeds or seed meal concentration may be from 5% to 35% by weight of whole cranberry fruit powder, such as from 10% to 25%, such as 20% of seeds or seed meal by weight of whole cranberry fruit powder.
  • the cranberry component may be a dried cranberry powder enriched with about 20% cranberry seed or seed meal by weight of dried cranberry powder.
  • the composition comprises less than about 12% of organic acids by weight, in some embodiments, the composition comprises less than 10% of organic acids by weight. In some embodiments, the composition comprises about 5% to about 8% of organic acids
  • the composition comprises less than about 15% of sugars by weight, such as lees than 12% or less than 10 % of sugars by weight.
  • the composition comprises from about 1 % to about 5% of quinic acid by weight. According to certain illustrative embodiments, the composition comprises from about 2.2% to about 3.2% of quinic acid by weight.
  • the composition comprises from about 0.4% to about 4% of malic acid by weight.
  • the composition comprises from about 1 % to about 5% of citric by weight. According to certain illustrative embodiments, the composition comprises from about 1.8% to about 3 .2% of citric acid by weight.
  • the composition comprises 0.5% to 5.0% proanthocyanidins, 0.05% to 1.5% quercetin, 0.001 % to 0.1 % quercetin-3-glucoside, 0.001 % to 0.1 % quercetin-3- rhamnoside, 0.001 % to 0.1 % quercetin-3-xyloside, 0.001 % to 0.1 % quercetin-3-arabinoside, 0.001 % to 0.5% myricetin, 0.001 % to 0.1 % peonidin-3-galactoside, 0.001 % to 0.1 % peonidin-3- glucoside, 0.001 % to 0.1 % peonidin-3-arabinoside, 0.001 % to 0.1 % cyanidin-3- glucoside, 0.001 % to 0.1 % cyanidin-3-galactoside, 0.001 % to 0.1 % cyanidin-3-galactoside, 0.001
  • the composition comprises 1.0% to 1.2% proanthocyanidins, 0.16% to 0.20% quercetin, 0.07% to 0.09% quercetin-3-glucoside, 0.03% to 0.04% quercetin-3- rhamnoside, 0.019% to 0.025% quercetin-3-xyloside, 0.025% to 0.035% quercetin-3- arabinoside, 0.010% to 0.014% myricetin, 0.022% to 0.030% peonidin-3-galactoside, 0.0025% to 0.0035% peonidin-3-glucoside, 0.010% to 0.020% peonidin-3-arabinoside, 0.0005% to 0.0015% cyanidin-3- glucoside, 0.015% to 0.030% cyanidin-3-galactoside, 0.010% to 0.025% cyanidin-3-arabinoside, 0.019% to 0.025% protocatechuic acid, 0.04% to 0.06% p-cou
  • the composition comprises about 1.1 % proanthocyanidins, 0.18% quercetin, 0.083% quercetin-3-glucoside, 0.034% quercetin-3-rhamnoside, 0.022% quercetin-3-xyloside, 0.030% quercetin-3-arabinoside, 0.012% myricetin, 0.027% peonidin-3- galactoside, 0.003% peonidin-3-glucoside, 0.014% peonidin-3-arabinoside, 0.001 % cyanidin-3- glucoside, 0.022% cyanidin-3-galactoside, 0.018% cyanidin-3-arabinoside, 0.022% protocatechuic acid, 0.052% p-coumaric acid, 0.021 % caffeoyl-glucoside, 0.011 % coumaroyl- glucoside, 0.014% caffeic acid, 0.034% chlorogenic acid or 0.92% ursolic acid
  • the composition comprises 1 to 100 pg lariciresinol, 1 to 100 pg secoisolariciresinol or 1 to 100 pg/ pinoresinol per 100 g of the composition by weight.
  • the composition comprises about 51 pg lariciresinol, about 12 pg secoisolariciresinol or about 78 pg/ pinoresinol per lOOg of the composition by weight.
  • the saponin component may be of natural (obtained or obtainable form a natural source rich in saponins) or of synthetic origin.
  • the saponin component used in the present invention may be selected from one or more of quillaja saponins, tea saponins, licorice saponins, beet root saponins, sugar beet saponins, ginseng saponins, glycyrrhizin, oat bran saponins, yucca saponins and mixtures thereof.
  • the saponin is quillaja saponin(s).
  • the saponin component is a natural extract, such as a quillaja extract, tea extract, licorice extract, beet root extract, sugar beet extract, ginseng extract, oat extract, yucca extract or a mixture thereof, with at least 5% wt/wt, or at least 10% wt/wt , or at least 15% wt/wt, or at least 20% wt/wt, or at least 25% wt/wt, or at least 30% wt/wt, or at least 35% wt/wt, or at least 40% wt/wt, or at least 50% wt/wt, or at least 60% wt/wt, or at least 70% wt/wt, or at least 80% wt/wt, or at least 95% wt/wt of saponins.
  • the saponin component may be a quillaja extract with at least 60% saponins, such as 65% wt/wt
  • the present disclosure is also related to a method for preventing, treating or alleviating an urinary tract infection, lower urinary tract symptoms (LUTS), the symptoms of benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, overactive bladder (OAB), bladder obstruction, interstitial cystitis, underactive bladder, prostatitis, bladder inflammation, prostate inflammation, prostate fibrosis, pelvic pain, H. pylori infection, urolithiasis, hyperoxaluria and/or pelvic organ prolapse, in a human or animal in need thereof, the method comprising administering to the patient an effective amount of a composition comprising a cranberry component and a saponin component.
  • the present disclosure is also related to a composition
  • a composition comprising a cranberry component and a saponin component for use in preventing, treating or alleviating an urinary tract infection, lower urinary tract symptoms (LUTS), the symptoms of benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, overactive bladder (OAB), bladder obstruction, interstitial cystitis, underactive bladder, prostatitis, bladder inflammation, prostate inflammation, prostate fibrosis, pelvic pain, H. pylori infection, urolithiasis, hyperoxaluria and/or pelvic organ prolapse.
  • the patient is a human or animal in the need thereof.
  • the present disclosure is also related to the use of a composition comprising a cranberry component and a saponin component in the preparation of a medicament or nutraceutical for preventing, treating or alleviating an urinary tract infection, lower urinary tract symptoms (LUTS), the symptoms of benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, overactive bladder (OAB), bladder obstruction, interstitial cystitis, underactive bladder, prostatitis, bladder inflammation, prostate inflammation, prostate fibrosis, pelvic pain, H. pylori infection, urolithiasis, hyperoxaluria and/or pelvic organ prolapse.
  • the patient is a human or animal in the need thereof.
  • a method for supporting genitourinary tract health in a human or animal in need thereof comprising administering to the human or animal an effective amount of a composition comprising a cranberry component and a saponin component.
  • the composition of the present disclosure can be used for treating urinary tract infections (UTIs) by itself.
  • the cranberry component can be used for treating urinary tract infections (UTIs) in combination with a NSAID.
  • a method for modulating or adjusting urinary tract and/or gut microbiota and/or reverting urinary tract and/or gut microbiome dysbiosis in a human or animal in need thereof comprising administering to the human or animal an effective amount of a composition (or composition of the disclosure) comprising a cranberry component and a saponin component.
  • composition comprising a cranberry component and a saponin component in the manufacture of a medicament for use in method for modulating or adjusting urinary tract and/or gut microbiota and/or reverting urinary tract and/or gut microbiome dysbiosis.
  • a method modulating or adjusting urinary tract and/or gut microbiota and/or reverting urinary tract and/or gut microbiome dysbiosis in a human or animal in need thereof, the method comprising administering to the human or animal an effective amount of a composition comprising a cranberry component and a saponin component and wherein.
  • the modulated or adjusted urinary tract and/or gut microbiota and/or reverted urinary tract and/or gut microbiome dysbiosis is selected from the group consisting of Dialister, Weeksella, Subdoligranulum, Fusicatenibacter, Leucobacter, Porphyromonas, Corynebacterium, Oligella, Sneathia, Prevotella_9, Blautia, Klebsiella, Bacteroides, Prevotella, Acinetobacter, Citrobacter, Faecalibacterium, Streptococcus, Lactobacillus, Escherichia, and combinations thereof.
  • the modulated or adjusted urinary tract and/or gut microbiota and/or reverted urinary tract and/or gut microbiome dysbiosis is Escherichia. In an embodiment, Escherichia abundance is decreased in the urinary tract.
  • Dysbiosis is often defined as an “imbalance” in for example the urinary or gut microbial community that is associated with disease. This imbalance could be due to the gain or loss of community members or changes in relative abundance of microbes.
  • microbiome diversity is increased, in particular the urine and/or gut microbiome diversity.
  • compositions comprising the composition of the invention (composition comprising a cranberry component and a saponin component) for use in the methods of treatment or uses described herein.
  • compositions comprising a cranberry component and a saponin component
  • the therapeutic composition or nutraceutical composition is formulated for oral administration.
  • compositions of the invention comprising the composition of the invention and optionally a physiologically acceptable excipient and/or carrier.
  • the composition of the present disclosure, the pharmaceutical composition, the nutraceutical composition or the food composition is provided in the form of a liquid, gel, tablet, a capsule, a sachet, a powder, a gum, an ointment, syrup, a suppository, a patch, a softgel, a tampon, a wound dressing, a wound rinse, a soap, or a lotion.
  • the composition of the present disclosure, the pharmaceutical composition or the nutraceutical composition is suitable for oral, rectal, intravenous, intravesical or vaginal delivery.
  • the composition of the present disclosure, the pharmaceutical composition or the nutraceutical composition comprises an enteric coating.
  • composition of the present disclosure, the pharmaceutical composition or the nutraceutical composition may be used in combination with probiotics.
  • the composition of the present disclosure, the pharmaceutical composition or the nutraceutical composition may be used in combination with an anti inflammatory agent.
  • composition of the present disclosure may be used in combination with an antimicrobial agent.
  • composition of the present disclosure when used in combination with antimicrobials promotes shorter treatment duration and lower dosage of antimicrobials, sparing the healthy microbiome.
  • composition of the present disclosure is used in prophylaxis to avoid the need for antimicrobial treatment, sparing the healthy microbiome.
  • a solid oral dosage comprising the composition described herein is a tablet, a capsule, or a softgel.
  • such solid oral dosage comprises from 50 mg to 1500 mg of the therapeutic composition, e.g., 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 800mg, 900mg, 1000 mg or 1500 mg.
  • the ratio of the cranberry component to the saponin component (such as quillaja saponin) in the composition is from 10:0.1 to 1:10, such as 10:0.1, 10:0.2, 10:0.3, 10:0.4, 10:05, 10:06, 10:0.7, 10:0.8, 10:0.9, 10:1, 10:1.1, 10:1.2, 10:1.3, 10:1.4, 10:1.5, 10:1.6, 10:1.7, 10:1.8, 10:1.9, 10:2, 10:3, 10:4, 10:4, 10:6, 10:7, 10:8, 10:9, 10:10, 9:10, 8:10, 7:10, 6:10, 5:10, 4:10, 3:10, 2:10 or 1:10.
  • the ratio is from 10:0.5 to 10:2, such as 10:0.7, 10:1, 10:1.1 or 10:1.5.
  • Solid dosage forms comprising the compositions described herein optionally comprise a suitable amount of one or more pharmaceutically acceptable excipients so as to provide the form for proper administration to the subject.
  • Such pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • the pharmaceutical excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like.
  • auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used.
  • the pharmaceutically acceptable excipients are sterile when administered to a subject.
  • Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like.
  • the present therapeutic compositions can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • the composition is in the form of a capsule (see, e.g., U.S. Patent No. 5,698,155).
  • suitable pharmaceutical excipients are described in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed. 1995).
  • compositions described herein are formulated in accordance with routine procedures as a composition adapted for oral administration to human beings (sch as a pharmaceutical composition or a nutraceutical composition).
  • Compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, softgels, syrups, or elixirs for example.
  • Orally administered compositions can contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation.
  • compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time.
  • Selectively permeable membranes surrounding an osmotically active therapeutic composition is also suitable for orally administered compositions.
  • fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture.
  • delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations.
  • a time delay material such as glycerol monostearate or glycerol stearate can also be useful.
  • Oral compositions can include standard excipients such as mannitol, lactose, starch, maltodextrin, cyclodextrins, alginate, arabic or guar gum, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate.
  • excipients are of pharmaceutical grade.
  • Pharmaceutical dosage forms for oral use can be obtained through combination of a therapeutic composition described herein with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable additional compounds, if desired, to obtain tablets or dragee cores.
  • Suitable solid excipients in addition to those previously mentioned are carbohydrate or protein fillers that include, but are not limited to, sugars, including lactose, sucrose, mannitol, or sorbitol; starch from com, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl-cellulose or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins such as gelatin and collagen.
  • Maltodextrin and cyclodextrins can also be used. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
  • Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredients is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
  • Softgels for oral use may consist of a gelatin based shell surrounding a liquid fill.
  • Softgel shells can be made of a combination of gelatin, water, opacifier and a plasticiser such as glycerin and/or sorbitol.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • Therapeutic compositions described herein can be administered by controlled-release or sustained release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.
  • Such dosage forms can be useful for providing controlled or sustained release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
  • Suitable controlled or sustained release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients of the invention.
  • the present disclosure thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled or sustained release.
  • a controlled or sustained release composition comprises a minimal amount of a therapeutic composition to alleviate the symptoms of, treat or prevent lower urinary tract symptoms (LUTS), urinary tract infections(UTIs), pelvic organ prolapse (POP), urolithiasis or hyperoxaluria, benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, interstitial cystitis, overactive bladder (OAB), underactive bladder, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain in a patient over a period of time.
  • Advantages of controlled or sustained release compositions include extended activity of the drug, reduced dosage frequency, and increased subject compliance.
  • controlled or sustained release compositions can favorably affect the time of onset of action or other characteristics, such as blood levels active ingredients present in the therapeutic composition, and can thus reduce the occurrence of adverse side effects.
  • Controlled or sustained release compositions can initially release an amount of an active ingredient present in the therapeutic composition that promptly produces the desired therapeutic or prophylactic effect, and gradually and continually release other amounts of the active ingredients present in the therapeutic composition to maintain this level of therapeutic or prophylactic effect over an extended period of time.
  • active ingredients present in the therapeutic composition thereof can be released from the dosage form at a rate that will replace the amount of the active ingredients present in the therapeutic composition being metabolized and excreted from the body.
  • Controlled or sustained release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds.
  • composition of the present disclosure comprising a cranberry component and a saponin
  • pharmaceutical composition or the nutraceutical composition that is useful for treating any of the diseases and symptoms described before (such as LUTS, OAB, etc) can be determined by standard clinical techniques.
  • in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges.
  • the precise dose to be employed can also depend on the route of administration, and the seriousness of the condition being treated and can be decided according to the judgment of the practitioner and each subject's circumstances in view of, e.g., published clinical studies.
  • Suitable effective dosage amounts range from about 1 mg to about 5 grams about every 24 hours, although they are typically about 500 mg or less per every 24 hours.
  • the effective dosage is about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg about 400 mg, about 450 mg about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1 g, about 1.2 g, about 1.4 g, about 1.6 g, about 1.8 g, about 2.0 g, about 2.2 g, about 2.4 g, about 2.6 g, about 2.8 g, about 3.0 g, about 3.2 g, about 3.4 g, about 3.6 g, about 3.8 g, about 4.0 g, about 4.2 g, about 4.4 g, about 4.6 g, about 4.8 g, and about 5.0 g, every 24 hours.
  • Equivalent dosages can be administered over various time periods including, but not limited to about every 2 hours, about every 4 hours, about every 6 hours, about every 8 hours, about every 24 hours, about every 36 hours, about every 48 hours, about every 72 hours, about every week, about every two weeks, about every three weeks, about every month, and about every two months.
  • the effective dosage amounts described herein refer to total amounts administered; that is, if more than one therapeutic composition is administered, the effective dosage amounts correspond to the total amount administered.
  • compositions described herein can be administered as long as the symptoms persist or longer.
  • the therapeutic composition is administered for 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 days.
  • the dosage regimen utilizing the therapeutic or nutraceutical compositions described herein can be selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the subject; the severity of the condition to be treated; the route of administration; and the renal or hepatic function of the subject.
  • a therapeutic or nutraceutical composition described herein can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily.
  • compositions described herein can be assayed in vitro or in vivo for the desired therapeutic or prophylactic activity prior to use in humans.
  • Animal model systems can be used to demonstrate safety and efficacy.
  • variable As used herein, the recitation of a numerical range for a variable is intended to convey that the invention may be practiced with the variable equal to any of the values within that range. Thus, for a variable which is inherently discrete, the variable can be equal to any integer value within the numerical range, including the end-points of the range. Similarly, for a variable which is inherently continuous, the variable can be equal to any real value within the numerical range, including the end-points of the range.
  • a variable which is described as having values between 0 and 2 can take the values 0, 1 or 2 if the variable is inherently discrete, and can take the values 0.0, 0.1, 0.01, 0.001, or any other real values > 0 and ⁇ 2 if the variable is inherently continuous.
  • treatment encompasses the improvement and/or reversal of the symptoms of disease (e.g. LUTS).
  • treatment refers to both therapeutic treatment and prophylactic or preventative measures.
  • those who may benefit from treatment with compositions, uses and methods of the present invention include those already with a disease and/or disorder (e.g., elevated cholesterol levels) as well as those in which a disease and/or disorder is to be prevented (e.g., using a prophylactic treatment of the present invention).
  • prevention in relation to a given disease or disorder means: preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be at risk or predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
  • the term “at risk for disease” refers to a subject (e.g., a human) that is predisposed to experiencing a particular disease.
  • This predisposition may be genetic (e.g., a particular genetic tendency to experience the disease, such as heritable disorders), or due to other factors (e.g., age, weight, environmental conditions, exposures to detrimental compounds present in the environment, etc.).
  • factors e.g., age, weight, environmental conditions, exposures to detrimental compounds present in the environment, etc.
  • a therapeutically effective amount of any embodiment of the present invention is determined using methods known to pharmacologists and clinicians having ordinary skill in the art. For example, an effective amount can be determined subjectively by administering increasing amounts of the compositions of the present invention until such time the patient being treated shows reduction in LUTS symptoms for example using the Urinary Tract Infection Symptoms Assessment Questionnaire (UTISA) as described in the experiments of the present invention,
  • UTISA Urinary Tract Infection Symptoms Assessment Questionnaire
  • Example 1 Clinical trial with a composition of Cranberry and quillaja.
  • the cranberry component is a dried cranberry powder that is enriched in 20% of cranberry seeds or seed meal by dry weight.
  • the quillaja component is an extract powder containing approximately 65% saponins by dry weight.
  • Time to symptom resolution is be determined using the Urinary Tract Infection Symptoms Assessment Questionnaire (UTISA),see tables 1 and 2. It assesses the degree of symptoms and bother on a scale of 0 to 3, and has 3 domains of urinary regularity, problems with urination and pain associated with urination. The fourth domain includes the presence of hematuria. Subjects complete UTISA every day for 14 days. 2) Time to UTI antibiotic initiation is assessed using study forms. Subjects have access to a clinically prescribed UTI antibiotic, nitrofurantoin. Subjects are asked to record each day their intake of any antibiotic during the study period.
  • UTISA Urinary Tract Infection Symptoms Assessment Questionnaire
  • Urinary and gut microbiome factors magnitude of initial dysbiosis, changes prior to antibiotic initiation if applicable, changes after antibiotic initiation, time to microbiome stability.
  • Vaccinium containing products e.g. all forms of blueberries, cranberries, bilberry, lingonberry etc. i.e. fruit, dried fruit, pills, juices or supplements
  • Screen failures are defined as participants who consent to participate in the clinical trial but are not subsequently entered in the study.
  • a minimal set of screen failure information is required to ensure transparent reporting of screen failure participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities.
  • Minimal information includes demography, screen failure details, and eligibility criteria.
  • Subjects have two in-office visits. At Visit 1, the subjects are required to provide a urine sample to test for leukocyte or nitrites, perform a urine culture and a pregnancy test. Subjects are also asked to provide a stool sample if possible. Recognizing that providing a stool sample at Visit 1 may not be possible, the subject take a stool sample at home and identify this as Day 1. After taking the stool sample the subjects begin taking the product substance immediately and then again that evening even if the first dose is taken in the afternoon and not the morning. The subjects shall then take the remaining product in the morning and evening as instructed until all 28 doses are gone and collect urine each day for 14 days and a second stool sample on Day 14 before returning for Visit 2.
  • Urine sample are collected at Visits 1, every day after Visit 1, and at Visit 2. Urine will be collected using Pez and AssayAssureTM urine collection kits. Each subject is asked to wash their hands with soap and water and collect midstream urine.
  • Pez midstream urine collection device allows the collection of approximately 30 mL of urine into a sterile container. It has been reported to allow the collection of urine that is significantly less contaminated with bacteria that was distinct from the periurethra compared to the standard clean catch method.
  • AssayAssureTM (Sierra Molecular Corp, Princeton, NJ) is a urine sample stabilization system designed to preserve cell viability by slowing cellular metabolism and providing thermal protection for up to 26 days at room temperature. After subjects collect urine using Pez collection device, the urine is transferred and stored in the AssayAssure transport tubes. The tubes are stored at a refrigerated temperature (2-4’C) and brought into clinic at Visit 2. The priority for the urine specimen on Visit 1 is clinical UTI testing (UA and reflex urine culture). All remaining urine from Visit 1 are saved for microbiome research purposes (sequencing of microbiome). A minimum sample quantity of 20 mL is need for the microbiome testing.
  • Subjects are instructed to take one 450 mg cranberry capsule, and one 50 mg quillaja capsule in the morning and another in the evening.
  • the total daily dosing will be 900 mg of cranberry, and 100 mg of quillaja per day for 14 days. If a subject is starting in the afternoon, they should take the morning dose at that time and then later take the evening dose. If subjects accidentally skip a dose they can double up on the next dose only if taken on the same day.
  • Urinary and gut microbiome factors such as the magnitude of initial dysbiosis, changes prior to antibiotic initiation will be measured.
  • the Statistical Package for the Social Sciences (SPSS, Chicago, IL) is used to perform all statistical analyses. Statistical significance is set at P ⁇ 0.05 a priori. Descriptive analyses are used to describe the characteristics of the patient sample (mean, standard deviation, percentages, and frequencies). One-way analysis of variance is used to evaluate the continuous variables, and chi-square tests is used to evaluate the categorical variables.
  • the probability is 80 percent that the study will detect a treatment difference at a two-sided 0.05 significance level, if the true difference pre and post treatment is a reduction of 7.5
  • Urine samples were processed within 6 hours of their collection as previously described (A1 and Burton, 2021). Fecal samples were collected on toilet paper and processed as previously described (A1 et al., 2018). Microbiota sequencing was performed on an Illumina MiSeq as previously described following PCR amplification of the V4 region of the 16S rRNA gene (Al et al., 2020). Raw reads were demultiplexed using Cutadapt (v3.4)(Martin, 2011) and quality filtered following the DADA2 pipeline (Callahan et al., 2016). The remaining filtered reads were assigned taxonomy to amplicon sequence variants (SVs) using the SILVA (vl38) training set (Quast et al., 2013). Downstream analysis was performed with ALDEx2, vegan, and core R packages (Fernandes et al., 2013; Oksanen et al., 2019; R Core team, 2019).
  • the microbiota was characterized for 13 samples from one participant, of which three were fecal and ten were urine per person.
  • the raw reads were stringently filtered for quality: of the initial average yield of 131 729 reads per sample, filtering pruned an average of 13%, such that approximately 117 000 reads per sample were maintained for the downstream analyses.
  • 2541 SVs were initially identified in the samples; a further filtering was performed such that SVs were removed that did not comprise >1% of the relative abundance in any sample, and did not assign to chloroplast, mitochondrial, or eukaryotic DNA. 116 SVs remained and were utilized for downstream analyses.
  • Figures la and lb show the relative bacterial abundance of all samples. Each vertical bar represents the relative SV abundance within a single sample. Samples are grouped by participant and sample type. Relative abundance of SVs is coloured by genera, with the 20 most abundant genera shown in the legend. Samples are coloured by sample type (fecal samples are gray, urine samples are yellow), and denoted with the day of sample collection. Figure la is in color, Figure lb in grayscale, but they show the same data.
  • Figures 2a and 2b show the relative bacterial abundance from baseline, midpoint, and day 14. Each vertical bar represents the relative SV abundance within a single sample. Samples are grouped by participant and sample type.
  • Relative abundance of SVs is coloured by genera, with the 20 most abundant genera shown in the legend.
  • Samples are coloured by sample type (fecal samples are gray, urine samples are yellow), and denoted with the day of sample collection.
  • Figure 2a is in color, Figure 2b in grayscale, but they show the same data.
  • participant 1 experienced a noticeable decrease in the severity and bothersome ratings of her symptoms at Day 14 (Table 3):

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des méthodes d'atténuation, de prévention, de réduction, de suppression et/ou de traitement d'une infection bactérienne chez un être humain ou un animal non humain. Les compositions et les méthodes sont utiles pour favoriser, par exemple, la santé du tractus génito-urinaire. Les méthodes peuvent comprendre l'administration à un humain ou à un animal en ayant besoin d'une quantité efficace d'une composition comprenant un composant de canneberge et un composant de saponine.
PCT/EP2021/071313 2021-03-07 2021-07-29 Méthodes et compositions pour le traitement et la prévention d'infections des voies urinaires WO2022189010A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163157790P 2021-03-07 2021-03-07
US63/157,790 2021-03-07

Publications (1)

Publication Number Publication Date
WO2022189010A1 true WO2022189010A1 (fr) 2022-09-15

Family

ID=77465959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/071313 WO2022189010A1 (fr) 2021-03-07 2021-07-29 Méthodes et compositions pour le traitement et la prévention d'infections des voies urinaires

Country Status (1)

Country Link
WO (1) WO2022189010A1 (fr)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059595A (en) 1989-03-22 1991-10-22 Bioresearch, S.P.A. Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form active in the therapy of organic mental disturbances
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5354556A (en) 1984-10-30 1994-10-11 Elan Corporation, Plc Controlled release powder and process for its preparation
US5639476A (en) 1992-01-27 1997-06-17 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5674533A (en) 1994-07-07 1997-10-07 Recordati, S.A., Chemical And Pharmaceutical Company Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US20030203054A1 (en) * 2001-09-25 2003-10-30 Jonathan Selzer Cranberry based dietary supplement and dental hygiene product
WO2009000277A1 (fr) * 2007-06-27 2008-12-31 Coloplast A/S Traitement d'infections des voies urinaires avec un mélange à base de saponine et d'un antibiotique
RO125750A0 (ro) * 2010-05-10 2010-10-29 Elzin Plant S.R.L. Compoziţie farmaceutică de supozitor pe bază de principii active naturale, pentru tratamentul afecţiunilor prostatei
CN103417424B (zh) * 2013-06-13 2014-12-31 星彤（上海）化妆品科技有限公司 一种植物本草洁、养、护女性护理凝露及其制备方法
WO2015070203A1 (fr) * 2013-11-11 2015-05-14 Naturex-Dbs Llc Compositions et méthodes utiles dans le traitement des symptômes des voies urinaires inférieures, de l'hyperplasie prostatique bénigne, et de la dysfonction érectile
RO132471A2 (ro) * 2016-10-31 2018-04-27 Hofigal Export - Import S.A. Produs natural fitoterapeutic, pentru afecţiuni ale vezicii urinare şi ale tractului reno-urinar, şi procedeu de obţinere a acestuia
CN108850077A (zh) * 2018-07-25 2018-11-23 贵州夜郎古国生物科技有限公司 一种防霉糕点及其制作方法
DE102018127408A1 (de) * 2018-11-02 2020-05-07 Ruhrpharm AG Cranberry-Extrakt-PAC-A-Zusammensetzung und dessen Verwendung bei der Prävention und/oder Behandlung von Harnwegsinfekten

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354556A (en) 1984-10-30 1994-10-11 Elan Corporation, Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5059595A (en) 1989-03-22 1991-10-22 Bioresearch, S.P.A. Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form active in the therapy of organic mental disturbances
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5639476A (en) 1992-01-27 1997-06-17 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5674533A (en) 1994-07-07 1997-10-07 Recordati, S.A., Chemical And Pharmaceutical Company Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension
US20030203054A1 (en) * 2001-09-25 2003-10-30 Jonathan Selzer Cranberry based dietary supplement and dental hygiene product
WO2009000277A1 (fr) * 2007-06-27 2008-12-31 Coloplast A/S Traitement d'infections des voies urinaires avec un mélange à base de saponine et d'un antibiotique
RO125750A0 (ro) * 2010-05-10 2010-10-29 Elzin Plant S.R.L. Compoziţie farmaceutică de supozitor pe bază de principii active naturale, pentru tratamentul afecţiunilor prostatei
CN103417424B (zh) * 2013-06-13 2014-12-31 星彤（上海）化妆品科技有限公司 一种植物本草洁、养、护女性护理凝露及其制备方法
WO2015070203A1 (fr) * 2013-11-11 2015-05-14 Naturex-Dbs Llc Compositions et méthodes utiles dans le traitement des symptômes des voies urinaires inférieures, de l'hyperplasie prostatique bénigne, et de la dysfonction érectile
RO132471A2 (ro) * 2016-10-31 2018-04-27 Hofigal Export - Import S.A. Produs natural fitoterapeutic, pentru afecţiuni ale vezicii urinare şi ale tractului reno-urinar, şi procedeu de obţinere a acestuia
CN108850077A (zh) * 2018-07-25 2018-11-23 贵州夜郎古国生物科技有限公司 一种防霉糕点及其制作方法
DE102018127408A1 (de) * 2018-11-02 2020-05-07 Ruhrpharm AG Cranberry-Extrakt-PAC-A-Zusammensetzung und dessen Verwendung bei der Prävention und/oder Behandlung von Harnwegsinfekten

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1995, pages: 1447 - 1676
AL, K.F.BISANZ, J.E.GLOOR, G.B.REID, G.BURTON J.P.: "Evaluation of sampling and storage procedures on preserving the community structure of stool microbiota: a simple at-home toilet-paper collection method", J. MICRO. METH., vol. 144, 2018, pages 117 - 121, XP085316087, DOI: 10.1016/j.mimet.2017.11.014
AL, K.F.BURTON J.P.: "Processing human urine and ureteral stents for 16S rRNA amplicon sequencing", STAR PROTOC., vol. 2, 2021, pages 100435
AL, K.F.DENSTEDT, J.D.DAISLEY, B.A.BJAZEVIC, J.WELK, B.K.PAUTLER, S.E.GLOOR, G.B.REID, G.RAZVI, H.BURTON J.P.: "Ureteral stent microbiota is associated with patient comorbidities but not antibiotic exposure", CELL REP. MED., vol. 1, 2020, pages 100094
CALLAHAN, B.J.MCMURDIE, P.J.ROSEN, M.J.HAN, A.W.JOHNSON, A.J.A.HOLMES, S.P.: "DADA2: High resolution sample inference from Illumina amplicon data", NAT. METHODS, vol. 13, 2016, pages 581 - 583
CLAYSON DWILD DDOLL HKEATING KGONDEK K.: "Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire", BJU INT., vol. 96, no. 3, August 2005 (2005-08-01), pages 350 - 9
FERNANDES, A.D.MACKLAIM, J.M.LINN, T.G.REID, G.GLOOR, G.B.: "ANOVA-like differential gene expression analysis of single-organism and meta-RNA-seq", PLOS ONE, vol. 8, 2013, pages e67019
GLOOR, G. B.MACKLAIM, J. M.PAWLOWSKY-GLAHN, V.EGOZCUE, J. J.: "Microbiome datasets are compositional: and this is not optional", FRONT. MICROBIOL., vol. 8, 2017, pages 2224
HOWELL AMY ET AL: "Comparison of the Anti-Adhesion Activity of Three Different Cranberry Extracts on Uropathogenic P-fimbriated Escherichia coli : A Randomized, Double-blind, Placebo Controlled, Ex Vivo , Acute Study", NATURAL PRODUCT COMMUNICATIONS, vol. 10, no. 7, 1 July 2015 (2015-07-01), US, XP055865881, ISSN: 1934-578X, Retrieved from the Internet <URL:https://journals.sagepub.com/doi/pdf/10.1177/1934578X1501000720> DOI: 10.1177/1934578X1501000720 *
MARTIN, M.: "Cutadapt removes adapter sequences from high-throughput sequencing reads", EMBNET J., vol. 17, 2011, pages 10 - 12
OKSANEN, J.F.BLANCHET, G.FRIENDLY, M.KINDT, R.LEGENDRE, P.MCGLINN, D.MINCHIN, P.R.O'HARA, R.B.SIMPSON, G.L.SOLYMOS, P. ET AL.: "vegan: Community Ecology Package", R PACKAGE, 2019, Retrieved from the Internet <URL:https://CRAN.R-project.org/package=vegan>
PASCU (NEAGU) MIHAELA ET AL: "Biologically active extracts with kidney affections applications", APPLIED SURFACE SCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 358, 14 September 2015 (2015-09-14), pages 647 - 654, XP029325793, ISSN: 0169-4332, DOI: 10.1016/J.APSUSC.2015.09.087 *
QUAST, C.PRUESSE, E.YILMAZ, P.GERKEN, J.SCHWEER, T.YARZA, P.PEPLIES, J.GLOCKNER, F.O.: "The SILVA ribosomal RNA gene database project: improved data processing and web-based tools", NUCL. ACIDS RES., vol. 41, 2013, pages D590 - D596, XP055252806, DOI: 10.1093/nar/gks1219
R CORE TEAM: "R: A language and environment for statistical computing", 2019, R FOUNDATION FOR STATISTICAL COMPUTING
VIDLAR ALES ET AL: "Cranberry fruit powder (Flowens(TM)) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study", WORLD JOURNAL OF UROLOGY, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 34, no. 3, 7 June 2015 (2015-06-07), pages 419 - 424, XP035875928, ISSN: 0724-4983, [retrieved on 20150607], DOI: 10.1007/S00345-015-1611-7 *

Similar Documents

Publication Publication Date Title
Wieërs et al. How probiotics affect the microbiota
Wu et al. Chitooligosaccharides prevents the development of colitis-associated colorectal cancer by modulating the intestinal microbiota and mycobiota
Zhang et al. Prevention of loperamide induced constipation in mice by KGM and the mechanisms of different gastrointestinal tract microbiota regulation
ES2960053T3 (es) Tratamiento de infección por Clostridium difficile
EP2040724B1 (fr) Compositions biothérapeutiques comprenant du escherichia coli probiotique et de la métronidazole, et leurs utilisations
JP6856968B2 (ja) 自閉症スペクトラム障害および関連する症候を治療するための方法
Bowe et al. Acne vulgaris, probiotics and the gut-brain-skin axis-back to the future?
El-Sayed et al. Microbiota and epigenetics: promising therapeutic approaches?
Bui et al. The gut-heart axis: updated review for the roles of microbiome in cardiovascular health
Yeom et al. Sasa quelpaertensis leaf extract regulates microbial dysbiosis by modulating the composition and diversity of the microbiota in dextran sulfate sodium-induced colitis mice
BR112016005059B1 (pt) Uso de uma composição compreendendo microrganismos para aumentar a produção intestinal de ácido butírico, ácido fólico ou niacina e/ou diminuição da produção intestinal de ácido succínico
US20180271919A1 (en) Probiotic composition at least comprising bifidobacterium bifidum w23 and capable of controlling intestinal barrier function
Lebeer et al. Topical cream with live lactobacilli modulates the skin microbiome and reduce acne symptoms
BR112020019979A2 (pt) Composições e métodos para tratamento de doenças inflamatórias intestinais
EP3024461B1 (fr) Combinaison d&#39;oxycodone et de la naloxone pour utilisation dans le traitement de la douleur chez des patients souffrant de douleurs et d&#39;une maladie résultant de dysbioses intestinales et/ou augmentant le risque de la la translocation bacterienne
Ha et al. Anti‐Inflammatory Effect of a Peptide Derived From the Synbiotics, Fermented Cudrania tricuspidata With Lactobacillus gasseri, on Inflammatory Bowel Disease
Tian et al. Overall structural alteration of gut microbiota and relationships with risk factors in patients with metabolic syndrome treated with inulin alone and with other agents: an open‐label pilot study
Compare et al. Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial
WO2022192854A1 (fr) Méthodes d&#39;induction de bioptérine et de métabolites apparentés
Guo et al. [Retracted] Effects of Irrational Use of Antibiotics on Intestinal Health of Children with Extraintestinal Infectious Diseases
WO2022189010A1 (fr) Méthodes et compositions pour le traitement et la prévention d&#39;infections des voies urinaires
US20250034656A1 (en) Methods for monitoring impact of microbiota transfer therapy in autism spectrum disorder (asd)
Kono et al. Distinct effects of TU-100 (daikenchuto) on long-lasting dysbiosis in the small intestine in patients with colorectal cancer and inflammatory bowel disease
US9895341B2 (en) Inflammation and immunity treatments
CA2623590C (fr) Preparation destinee a traiter des maladies intestinales inflammatoires non infectieuses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21759033

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21759033

Country of ref document: EP

Kind code of ref document: A1